INVESTORS

Investor Relations

Recent News
Aug 9, 2018

- SRA737 Monotherapy trial prioritized for ovarian cancer; targeting enrollment of 65 patients with preliminary data anticipated in H1 2019 - - SRA737 LDG Combination trial to be amended and...

Aug 7, 2018

Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with...

May 30, 2018

Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with...

View all news releases

Events and Webcasts
Wednesday, August 15, 2018
9:10am EDT

Location: New York, New York

View all events and webcasts

Investor Enquiries

James Smith, Vice President Corporate Affairs
investors@sierraoncology.com

Sign up for investor alerts